Adefovir-induced Fanconi syndrome associated with osteomalacia
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Fanconi syndrome is a dysfunction of the proximal renal tubules that results in impaired reabsorption and increased urinary loss of phosphate and other solutes. The pathophysiology of drug-induced Fanconi syndrome is unclear. Here we report the case of a 36-year-old woman who presented with pain in multiple bones and proteinuria. She had a 7-year history of taking adefovir at 10 mg/day for chronic hepatitis B. Three years previously she had received surgery for a nontraumatic right femur neck fracture, after which she continued to complain of pain in multiple bones, and proteinuria, glycosuria, and phosphaturia were noted. The findings of a light-microscope examination of a renal biopsy sample were normal, but mitochondrial damage of the proximal tubules was evident in electron microscopy. Western blot analysis revealed that the level of serum fibroblast growth factor 23 (FGF23) was lower than in normal controls. After 2 months of treatment, hypophosphatemia and proximal tubular dysfunction were reversed, and serum FGF23 had normalized. This case suggests that direct mitochondrial damage in proximal tubules can cause drug-induced Fanconi syndrome associated with osteomalacia.
Abstract
Fanconi syndrome is a dysfunction of the proximal renal tubules that results in impaired reabsorption and increased urinary loss of phosphate and other solutes. The pathophysiology of drug-induced Fanconi syndrome is unclear. Here we report the case of a 36-year-old woman who presented with pain in multiple bones and proteinuria. She had a 7-year history of taking adefovir at 10 mg/day for chronic hepatitis B. Three years previously she had received surgery for a nontraumatic right femur neck fracture, after which she continued to complain of pain in multiple bones, and proteinuria, glycosuria, and phosphaturia were noted. The findings of a light-microscope examination of a renal biopsy sample were normal, but mitochondrial damage of the proximal tubules was evident in electron microscopy. Western blot analysis revealed that the level of serum fibroblast growth factor 23 (FGF23) was lower than in normal controls. After 2 months of treatment, hypophosphatemia and proximal tubular dysfunction were reversed, and serum FGF23 had normalized. This case suggests that direct mitochondrial damage in proximal tubules can cause drug-induced Fanconi syndrome associated with osteomalacia.
참고문헌 (17)
- Kahn J, "Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial", JAMA, 282, pp.2305~2312 (1999)[DOI]
- Hadziyannis SJ, "Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B", N Engl J Med, 348, pp.800~807 (2003)[DOI]
- 정영걸, "Fanconi’s Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient", Gut and Liver, 4(3), pp.389~393 (2010), 거트앤리버 소화기연관학회협의회
- Girgis CM, "Hypophosphataemic osteomalacia in patients on adefovir dipivoxil", J Clin gastroenterol, 45, pp.468~473 (2011)[DOI]
- Laing CM, "Renal tubular acidosis: developments in our understanding of the molecular basis", Int J Biochem Cell Biol, 37, pp.1151~1161 (2005)[DOI]
- Earle KE, "Fanconi's syndrome in HIV+ adults: report of three cases and literature review", J Bone Miner Res, 19, pp.714~721 (2004)[DOI]
- Endo I, "Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement", Bone, 42, pp.1235~1239 (2008)[DOI]
- Saidenberg-Kermanac'h N, "Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease", Joint Bone Spine, 78, pp.306~308 (2011)[DOI]
- Saeedi R, "Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia", Calcif Tissue Int, 94, pp.665~668 (2014)[DOI]
- Ichchou L, "Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir", Joint Bone Spine, 80, pp.668~669 (2013)[DOI]
- Goto S, "Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome-induced hypophosphatemia", Clin Kidney J, 9, pp.677~681 (2016)[DOI]
- Hall AM, "Drug-induced renal Fanconi syndrome", QJM, 107, pp.261~269 (2014)[DOI]
- Taylor SC, "A defined methodology for reliable quantification of Western blot data", Mol Biotechnol, 55, pp.217~226 (2013)[DOI]
- Juppner H, "Phosphate and FGF-23", Kidney Int Suppl, 79121, pp.S24~S27 (2011)
- Filler G, "Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease", Clin Biochem, 44, pp.435~437 (2011)[DOI]
- Goto S, "Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease", Clin Exp Nephrol, 18, pp.925~931 (2014)[DOI]
- Kidney Disease: Improving Global Outcomes CKD Work Group, "KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease", Kidney Int, 3, pp.1~150 (2013)[DOI]